Evaluation of Aminoglycoside and Non-Aminoglycoside Compounds for Stop-Codon Readthrough Therapy in Four Lysosomal Storage Diseases.
Nonsense mutations are quite prevalent in inherited diseases. Readthrough drugs could provide a therapeutic option for any disease caused by this type of mutation. Geneticin (G418) and gentamicin were among the first to be described. Novel compounds have been generated, but only a few have shown imp...
Main Authors: | Marta Gómez-Grau, Elena Garrido, Mónica Cozar, Víctor Rodriguez-Sureda, Carmen Domínguez, Concepción Arenas, Richard A Gatti, Bru Cormand, Daniel Grinberg, Lluïsa Vilageliu |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4545610?pdf=render |
Similar Items
-
Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides
by: Jamie R Wangen, et al.
Published: (2020-01-01) -
Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy
by: Vinod Malik, et al.
Published: (2010-11-01) -
The antimalarial drug mefloquine enhances TP53 premature termination codon readthrough by aminoglycoside G418.
by: Michael W Ferguson, et al.
Published: (2019-01-01) -
Heterologous stop codon readthrough of metazoan readthrough candidates in yeast.
by: Clara S Chan, et al.
Published: (2013-01-01) -
Heterologous Stop Codon Readthrough of Metazoan Readthrough Candidates in Yeast
by: Jungreis, Irwin, et al.
Published: (2013)